Compliance & Validation — Documented
SOC 2 Type II
IntegriChain
Pharma market access and commercialization data platform (ICyte) applying analytics and AI across payer, patient, and channel data.
IntegriChain, headquartered in Philadelphia, Pennsylvania, provides the ICyte platform for pharmaceutical market access and commercialization — spanning gross-to-net, government pricing, patient services, and distribution channel data — with analytics and AI applied across these data assets. Nordic Capital holds a majority share, and the company continues to operate under its own brand with its own leadership. Its newsroom documents completed SOC examinations; request the current SOC 2 report during evaluation.
- Headquarters
- Philadelphia, United States
- Compliance
- SOC 2 Type II
- Deployment options
- cloud
- Website
- https://www.integrichain.com
- https://www.linkedin.com/company/integrichain
Categories
AI Use Cases
- Market Access & HTA Strategy
Vendor Scorecard
64% — Partial coverage. Coverage score — how completely Atlas documents IntegriChain across 7 buyer-evaluation areas. Reflects available Atlas data, not solution quality.
Deployment & Hosting — Documented
cloud
Pricing Transparency — Not documented by Atlas
Ask the vendor: What is your pricing model, and what drives total cost of ownership?
Implementation & Onboarding — Not documented by Atlas
Ask the vendor: What is a realistic implementation timeline, and what onboarding support is included?
Organization & Role Fit — Documented
Mid-Size Biotech, Large Pharma, Top 20 Pharma, Commercial, Data Management
Solution Scope — Documented
Market Access Analytics
Company Viability — Partially documented
Private equity
Always ask the vendor
Not captured in Atlas data — confirm directly. Excluded from the score above.
Data Rights & IP
Who owns model outputs? Is our proprietary data used to train models others can access, and where does our data reside?
Model Credibility & Explainability
Can you share validation studies or benchmarks, explain how the model reaches its conclusions, and describe how bias and drift are monitored?
Questions to Ask This Vendor
- What period does the current SOC 2 report cover?
- Which modules (gross-to-net, patient services, channel) are most mature?
- How does AI factor into the analytics versus rules-based reporting?
- What does implementation look like alongside our existing data warehouse?